Canaccord reiterates Hims and Hers stock rating after Novo deal By Investing.com

Hims & Hers announced a partnership with Novo Nordisk to offer Ozempic and Wegovy (oral and injectable) and Novo Nordisk dismissed its lawsuit without prejudice; the collaboration is expected to launch late March or early April. The stock has surged ~40% over the past week to $22.16 (market cap ~$5.05B) and the company reported 59% revenue growth over the last 12 months. Several analysts raised or reiterated ratings (Canaccord/Needham $30 PTs, Needham upgraded to Buy) while others remained cautious (Truist Hold $18, BofA Underperform $12.50, BTIG Neutral citing margin pressure); pricing and partnership economics remain unclear.

Analysis

The Novo–Hims tie-up shifts the economics of direct-to-consumer GLP-1 distribution from a high-margin compounding channel to a high-volume, lower-margin branded channel; that means Hims' headline revenue per script will likely fall even as gross script count rises. Second-order winners are platform owners with strong subscription cross-sell (HIMS), and losers are opaque compounding intermediaries that relied on price spreads — expect margin compression across the DTC cohort unless HIMS negotiates favorable rebates or fulfillment fees.

Market share dynamics in obesity/GLP-1 are now a two-front battle: product efficacy/brand (Novo/Lilly) versus convenience and price (Hims & other DTC vendors). If Novo controls supply and pricing via selective DTC distribution, it can blunt discount competition but also limit conversion from price-sensitive Hims customers; the fulcrum will be the conversion rate from compounded users to branded prescriptions and the pace at which payers/PCPs accept DTC-sourced branded scripts.

Key catalysts and timelines: expect the operational impact to appear in HIMS KPIs within 1–2 quarters (prescription mix, gross margin per script) and in Novo’s volumes over 2–6 quarters as channel substitution plays out. Tail risks that would reverse the trade include unexpected payer pushback or a rapid, sustained share gain by Lilly in obesity medicines that re-centers prescribing away from Novo, and regulatory scrutiny of DTC fulfilment that could slow rollout materially.

Key Decisions for Investors

• Long HIMS equity vs protection: Buy HIMS (ticker HIMS) with a 6–12 month horizon. If you want asymmetric upside while capping downside, buy a Mar-2027 $25/$35 call spread instead of shares; target payoff to $30+ if conversion and cross-sell lift ARPU. Hedge with a 10–15% stop on the equity leg or limit cost basis on the spread to preserve 2:1+ upside against premium paid.
• Pair trade: Long HIMS / Short NVO on 3–9 month view to capture DTC distribution arbitrage. Rationale: HIMS captures incremental customer LTV; NVO absorbs margin pressure from DTC partnerships. Size the short smaller (25–50% notional of the HIMS long) to limit tail risk from product outperformance by NVO; use 3–6 month put spreads on NVO for defined risk if a direct short is undesirable.
• Options hedge for existing HIMS longs: Sell covered calls at the $30 strike 3–6 months out to monetize near-term optimism while retaining upside to $30; if you want downside protection without giving up upside, buy 3–6 month puts (protect to a predefined loss level) funded by selling OTM calls.
• Event hedge / tactical short: Buy 3–6 month puts on competitors gaining share (e.g., LLY if prescription trends accelerate materially) or add a small short exposure to any publicly listed compounding proxies after confirming revenue mix — use tight expiries and size small (5–7% portfolio) because regulatory/prescription shifts can be binary and fast.